MB
LNTH icon

MPM BioImpact’s Lantheus LNTH Stock Holding History

MPM BioImpact’s Portfolio LNTH Stock Details LNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-232,387
Closed -$22.7M – 49
2025
Q1 		$22.7M Sell
232,387
-3,826
-2% -$358K 3.9% 5
2024
Q4 		$21.1M Buy
236,213
+86,031
+57% +$8.38M 3% 8
2024
Q3 		$16.5M Buy
150,182
+182
+0.1% +$18.9K 2.47% 14
2024
Q2 		$12M Buy
+150,000
New +$11M 1.87% 18

Other funds holding LNTH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

MPM BioImpact's LNTH Position: Q2 2025 in Review

MPM BioImpact sold out of Lantheus (LNTH) in Q2 2025, closing a stake of 232,387 shares — an estimated $22.7M sold.

MPM BioImpact first reported a position in LNTH in Q2 2024 and held it in 4 quarters. The position peaked at $22.7M in Q1 2025. 475 funds tracked by Wall St. Rank hold LNTH as of Q2 2025.

  • MPM BioImpact reported no remaining Lantheus position as of Q2 2025 after selling out during the quarter.
  • MPM BioImpact sold 232,387 Lantheus shares in Q2 2025, an estimated $22.7M.
  • MPM BioImpact first reported a position in Lantheus in Q2 2024 and held it in 4 quarters.
  • MPM BioImpact's Lantheus position peaked at $22.7M in Q1 2025.
  • 475 funds tracked by Wall St. Rank held Lantheus as of Q2 2025.

Based on MPM BioImpact's 13F filing for Q2 2025, filed 14 Aug 2025.